Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

What we know and what we should know on immunotherapy and endometrial cancer (EC)

Should IO be considered the new standard of care in advanced EC?

Date

15 Sep 2024

Session

What we know and what we should know on immunotherapy and endometrial cancer (EC)

Topics

Tumour Site

Gynaecological Malignancies

Presenters

Ana Oaknin

Authors

A. Oaknin

Author affiliations

Medical Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

15 Sep 2024

Digging into the biology: Who are the responders?

Presenter: Xavier Matias-Guiu

Session: What we know and what we should know on immunotherapy and endometrial cancer (EC)

Resources:

Slides

Webcast

15 Sep 2024

Enhancing the checkpoints' activity in pMMR

Presenter: Vicky Makker

Session: What we know and what we should know on immunotherapy and endometrial cancer (EC)

Resources:

Slides

Webcast

15 Sep 2024

Overcoming the resistance to IO: What can we do?

Presenter: Frederik Marmé

Session: What we know and what we should know on immunotherapy and endometrial cancer (EC)

Resources:

Slides

Webcast

15 Sep 2024

Q&A and discussion

Session: What we know and what we should know on immunotherapy and endometrial cancer (EC)

Resources:

Webcast